En Es
Categories

Industry News

Hill-Rom Holdings to Acquire Mortara Instrument

By HospiMedica International staff writers
12 Jan 2017

Image: Hill-Rom has acquired Mortara Instrument for USD 330 million (Photo courtesy of iStock).Hill-Rom Holdings, Inc. (Batesville, IN, USA), a provider of patient care solutions to health care providers, has signed a definitive agreement to acquire Mortara Instrument, Inc. (Milwaukee, WI, USA), a privately held company offering diagnostic cardiology and patient monitoring solutions, technologies and devices.

Hill-Rom offers patient care solutions in five core areas: advancing mobility, wound care and prevention, patient monitoring and diagnostics, surgical safety and efficiency, and respiratory health. The company’s patient care solutions include hospital beds, wound therapy systems, support surfaces and mattresses, patient handling/support systems, respiratory care products, clinical workflow solutions, and surgical equipment, among others.

Mortara's portfolio includes diagnostic cardiology devices for monitoring resting electrocardiography (ECG), cardiac stress exercise, Holter, ambulatory blood pressure, and cardiac and pulmonary rehabilitation and multiple patient parameters.

The USD 330 million cash deal is expected to enhance Hill-Rom’s presence in cardiac technology as well as allow it to offer a more comprehensive suite of continuous vital signs monitoring parameters.

"Our growing Welch Allyn franchise will be immediately strengthened by the addition of Mortara Instrument's experienced team, breadth of diagnostic cardiology and patient monitoring offerings and best-in-class ability to integrate with electronic medical record (EMR) systems," said Hill-Rom President and CEO John J. Greisch. "With Mortara, we will expand our diagnostic cardiology franchise in the acute care, clinical research and primary care settings, where we will use our global commercial presence to accelerate growth of the Mortara business. This transaction is aligned with our strategy to expand in our clinical focus areas, in this case patient diagnostics and monitoring, through the addition of complementary innovative solutions and enhanced customer offerings to deliver value for shareholders."

Mr. Greisch continued, "We look forward to welcoming the talented employees of Mortara to the Hill-Rom team. With our shared mission, global reach and complementary products, we anticipate a successful integration and rapid commercialization of new products. Together, we will offer our customers around the globe a broader range of diagnostic technologies to further our mission of improving outcomes for patients and their caregivers."

"By combining with Hill-Rom, Mortara Instrument will have greater opportunities to grow as part of a global leader with strong brand equity and unparalleled care setting expertise," said Mortara Instrument CEO Dr. Justin Mortara. "Hill-Rom and Mortara Instrument share similar patient-centric cultures, and I am confident that this combination will benefit our valued employees and customers. I look forward to working with the entire Hill-Rom team as we enter our next phase of success."

Related Links
Hill-Rom
Mortara Instrument



E-mail Print
FaceBook Twitter Google+ Linked in

Hill-Rom

Manufactures and provides patient support systems, safe mobility and handling solutions, non-invasive therapeutic products for acute and chronic medical conditions, medical equipment rentals, surgical products and information technology solutions
More info

Additional news

24 Sep 2018
Chinese AI System Designed to Predict Diabetes Years in Advance
4 Paradigm, a technology company, is working with Ruijin Hospital to develop a new artificial intelligence (AI) system that will help them to identify patients at risk of developing diabetes up to 15 years in advance. The model named Ruining Knows Sugar, or Ruining Zhitang in Chinese, has achieved an accuracy rate of 88% in tests.
Read More
24 Sep 2018
AI Applied to Micro-Ultrasound Could Speed Cancer Detection
Cambridge Consultants and Exact Imaging are working together to improve the way prostate cancer is visualized and detected by applying deep learning to high-resolution micro-ultrasound imaging. This can help identify potential suspicious regions of tissue and inform urologists who may want to consider this additional data in their biopsy protocol. The early results of their work have been promising.
Read More
24 Sep 2018
AI Program Could Aid Decision-Making in Medical Imaging
Researchers are developing a first of its kind neural network that explains itself and could help with decision-making in the medical field, among others. Raytheon BBN Technologies is developing the neural network under the Defense Research Project Agency's (DARPA) Explainable Artificial Intelligence program (XAI). The aim of the XAI program is to create a suite of machine learning techniques, which produce more explainable models while maintaining a high level of performance. It also aims to help human users understand, appropriately trust and effectively manage the emerging generation of artificially intelligent partners.
Read More
24 Sep 2018
Tetris-Like Program Could Speed Up Breast Cancer Detection
A fully automated medical image analysis program to detect breast tumors that uses a unique style to focus on the affected area is being developed by researchers from the University of Adelaide’s Australian Institute for Machine Learning. Using artificial intelligence (AI), the autonomous program in conjunction with an MRI scan employs the traversal movement and style of a retro video game to examine the breast area.
Read More
20 Sep 2018
Increasing Conditions and Diseases Drive Global POC Hematology Diagnostics Market
The global Point of Care (POC) hematology diagnostics market is expected to grow at a CAGR of close to 9% over the forecast period 2018-2022 to reach a value of USD 2.7 billion by 2022, driven mainly by the rising prevalence of hematology conditions and infectious diseases such as sickle cell disease, thalassemia, and polycythemia. Additionally, the increased adoption of next-generation hematology diagnostic products such as handheld hematology devices and non-invasive hematology testing will further contribute to the growth of the global POC hematology diagnostics market.
Read More
20 Sep 2018
Western Blotting Processors Market to Reach USD 329 Million by 2028
The western blotting processors market is projected to grow at a CAGR of 5.1% from an estimated USD 200 million in 2018 to just under USD 329 million towards the end of 2028, driven partly by the increasing cases of HIV globally as western blot is a confirmed test that can detect anti-HIV antibodies in blood serum samples.
Read More
18 Sep 2018
Digital X-ray Market to Reach USD 13 Billion by 2023
The digital X-ray market is expected to grow at a CAGR of 8.5% from USD 8.68 billion in 2018 to USD 13.04 billion by 2023, driven by a growing geriatric population and resultant increase in the incidence of global diseases, favorable regulations and government initiatives & investments, increased advantages of digital X-ray systems, and technological advancements and product development.
Read More
18 Sep 2018
Study Examines How Medical Device Industry Can Increase Success
An aging global population, growing health awareness, and rising income levels in most emerging markets are driving the need and opportunity for high-quality medical device solutions in these regions. However, in order to capture market share in growth regions such as Asia-Pacific (APAC) and Latin America (LATAM), medical device organizations need to align their emerging-market strategies and business models in line with the regulatory and business landscapes prevailing in the target countries and markets.
Read More
12 Sep 2018
Researchers Develop AI Algorithm to Predict Immunotherapy Response
A team of French researchers have designed an algorithm and developed it to analyze Computed Tomography (CT) scan images, establishing for the first time that artificial intelligence (AI) can process medical images to extract biological and clinical information. The researchers have created a so-called radiomic signature, which defines the level of lymphocyte infiltration of a tumor and provides a predictive score for the efficacy of immunotherapy in the patient.
Read More
Copyright © 2000-2018 TradeMed.com. All rights reserved. | Terms And Conditions